The Challenges in Diagnosis and Management of Acquired Thrombotic Thrombocytopenic Purpura: Consensus Report from Three Gulf Countries

Murtadha Al-Khabori 1, Faisal Alsayegh 2, Hasan Al Yaseen 3, Sabir Hussien 4, Amar Lal 4, Muna Al Rasheed 5, Mohammad Al Bader 6, Salam Al Kindi 1, Mahmoud Marashi 3

Affiliations

doi: 10.5001/omj.2022.32

Abstract

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare hematological emergency characterized by microangiopathic hemolytic anemia, thrombocytopenia, fever, and multiorgan failure due to autoimmune-mediated deficiency in ADAMTS-13 activity. Currently, plasma exchange, with or without steroids, is the frontline option for the management of aTTP. The treatment should be started promptly once the disorder is clinically suspected. Besides, immunomodulators were studied in patients with aTTP to achieve stable remission and reduce the risk of relapse in patients with suboptimal response to plasma exchange; however, clinical trials showed equivocal results. Published data on early diagnosis, referral, and treatment patterns of aTTP patients in the member nations of the Arabian Gulf Cooperation Council (GCC) are still lacking. Therefore, the present consensus report aimed to present an overview of aTTP situation in GCC by bringing together a panel of experts from three GCC nations, to share their views on current trends and practices regarding aTTP. The experts discussed challenges including the lack of reliable data regarding the incidence of aTTP in GCC and delayed results of ADAMTS-13 activity testing. Limited patient access to tertiary centers and low level of awareness about the aTTP clinical spectrum among general practitioners are other challenges. The experts agreed that there is a need for national and regional consensus regarding the diagnosis and treatment of aTTP in the Gulf region.

Keywords: Kuwait; Microangiopathic Hemolytic Anemia; Oman; Purpura, Thrombotic Thrombocytopenic; Thrombosis; United Arab Emirates.

 

Similar articles

An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.

Roose E, Schelpe AS, Joly BS, Peetermans M, Verhamme P, Voorberg J, Greinacher A, Deckmyn H, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.J Thromb Haemost. 2018 Feb;16(2):378-388. doi: 10.1111/jth.13922. Epub 2018 Jan 23.PMID: 29222940

The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age.

Agosti P, Mancini I, Artoni A, Ferrari B, Pontiggia S, Trisolini SM, Facchini L, Peyvandi F; Italian Group of TTP Investigators.Thromb Res. 2020 Mar;187:197-201. doi: 10.1016/j.thromres.2019.10.010. Epub 2019 Oct 22.PMID: 31685248

Systematic thematic review of e-health research in the Gulf Cooperation Council (Arabian Gulf): Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates.

Weber AS, Turjoman R, Shaheen Y, Al Sayyed F, Hwang MJ, Malick F.J Telemed Telecare. 2017 May;23(4):452-459. doi: 10.1177/1357633X16647894. Epub 2016 May 28.PMID: 27236702

Clinical Review Report: Caplacizumab (Cablivi): (Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.): Indication: Indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PEX) and immunosuppressive therapy [Internet].

[No authors listed]Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Oct.PMID: 33600100 Free Books & Documents. Review.

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.

Gómez-Seguí I, Fernández-Zarzoso M, de la Rubia J.Expert Rev Hematol. 2020 Nov;13(11):1153-1164. doi: 10.1080/17474086.2020.1819230. Epub 2020 Oct 12.PMID: 32876503 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Zuno J, Khaddour K. Thrombotic thrombocytopenic purpura evaluation and management- StatPearls - NCBI Bookshelf. StatPearls; 2020. - PubMed
  2.  
    1. Rizzo C, Rizzo S, Scirè E, Di Bona D, Ingrassia C, Franco G, et al. . Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange. Blood Transfus 2012. Oct;10(4):521-532. - PMC - PubMed
  3.  
    1. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Vol. 112, Blood. American Society of Hematology; 2008. p. 11-8. - PMC - PubMed
  4.  
    1. Deford CC, Reese JA, Schwartz LH, Perdue JJ, Kremer Hovinga JA, Lämmle B, et al. . Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013. Sep;122(12):2023-2029, quiz 2142. 10.1182/blood-2013-04-496752 - DOI - PMC - PubMed
  5.  
    1. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010. Feb;115(8):1500-1511, quiz 1662. 10.1182/blood-2009-09-243790 - DOI - PubMed
  6.  
    1. Goel R, King KE, Takemoto CM, Ness PM, Tobian AA. Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. Transfusion 2016. Jun;56(6):1451-1458. 10.1111/trf.13586 - DOI - PMC - PubMed
  7.  
    1. Miesbach W, Menne J, Bommer M, Schönermarck U, Feldkamp T, Nitschke M, et al. . Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study. Orphanet J Rare Dis 2019. Nov;14(1):260. 10.1186/s13023-019-1240-0 - DOI - PMC - PubMed
  8.  
    1. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. British Committee for Standards in Haematology . Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012. Aug;158(3):323-335. 10.1111/j.1365-2141.2012.09167.x - DOI - PubMed
  9.  
    1. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Vol. 129, Blood. American Society of Hematology; 2017. p. 2836-2846. - PubMed
  10.  
    1. Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, et al. . Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost 2020. Feb;18(2):479-484. 10.1111/jth.14679 - DOI - PMC - PubMed
  11.  
    1. Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, et al. French Reference Center for Thrombotic Microangiopathies . Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 2016. May;3(5):e237-e245. 10.1016/S2352-3026(16)30018-7 - DOI - PubMed
  12.  
    1. Schönermarck U, Ries W, Schröppel B, Pape L, Dunaj-Kazmierowska M, Burst V, et al. . Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J 2019. Jun;13(2):208-216. 10.1093/ckj/sfz066 - DOI - PMC - PubMed
  13.  
    1. Török TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States–analysis of national mortality data, 1968-1991. Am J Hematol 1995. Oct;50(2):84-90. 10.1002/ajh.2830500203 - DOI - PubMed
  14.  
    1. Miller DP, Kaye JA, Shea K, Ziyadeh N, Cali C, Black C, et al. . Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology 2004. Mar;15(2):208-215. 10.1097/01.ede.0000113273.14807.53 - DOI - PubMed
  15.  
    1. Iqbal S, Zaidi SZ, Motabi IH, Alshehry NF, AlGhamdi MS, Tailor IK. Thrombotic thrombocytopenic purpura - analysis of clinical features, laboratory characteristics and therapeutic outcome of 24 patients treated at a Tertiary Care Center in Saudi Arabia. Pak J Med Sci 2016. Nov-Dec;32(6):1494-1499. 10.12669/pjms.326.11274 - DOI - PMC - PubMed
  16.  
    1. Al Hashmi KN, Al Dowaiki S. Thrombotic thrombocytopenic purpura in oman; manifestations and outcome. retrospective study. Blood 2018. Nov;132(Supplement 1):5004-5004 .10.1182/blood-2018-99-115227 - DOI
  17.  
    1. Al-Awadhi AM, Jadaon MM, Al-Jafar HA, Al-Wazzan HJ. ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait. Acta Haematol 2011;125(3):160-166. 10.1159/000322391 - DOI - PubMed
  18.  
    1. Jang MJ, Chong SY, Kim IH, Kim JH, Jung CW, Kim JY, et al. . Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. Int J Hematol 2011. Feb;93(2):163-169. 10.1007/s12185-011-0771-5 - DOI - PubMed
  19.  
    1. Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, et al. . Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008. Sep;142(5):819-826. 10.1111/j.1365-2141.2008.07276.x - DOI - PubMed
  20.  
    1. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med 2010;49(1):7-15. 10.2169/internalmedicine.49.2706 - DOI - PubMed
  21.  
    1. Sarode R. Atypical presentations of thrombotic thrombocytopenic purpura: a review. J Clin Apher 2009;24(1):47-52. 10.1002/jca.20182 - DOI - PubMed
  22.  
    1. Sadler JE. What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2015;2015(1):631-636. 10.1182/asheducation-2015.1.631 - DOI - PMC - PubMed
  23.  
    1. George JN, Al-Nouri ZL. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Vol. 2012, Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. American Society of Hematology; 2012. p. 604-609. - PubMed
  24.  
    1. Veyradier A, Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 2005. Nov;3(11):2420-2427. 10.1111/j.1538-7836.2005.01350.x - DOI - PubMed
  25.  
    1. Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, et al. Reference Center for Thrombotic Microangiopathies. Experience of the French Thrombotic Microangiopathies Reference Center . Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2015. Feb;13(2):293-302. 10.1111/jth.12790 - DOI - PubMed
  26.  
    1. Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, et al. . Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology (Carlton) 2018. Jun;23(6):507-517. 10.1111/nep.13234 - DOI - PubMed
  27.  
    1. Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. . Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 2017. Apr;4(4):e157-e164. 10.1016/S2352-3026(17)30026-1 - DOI - PubMed
  28.  
    1. Wynick C, Britto J, Sawler D, Parker A, Karkhaneh M, Goodyear D, et al. . Validation of the plasmic score for predicting ADAMTS13 activity < 10% in patients admitted to hospitals in Alberta with suspected thrombotic thrombocytopenic purpura. Blood 2019. Nov;134(Supplement_1):2379-2379 .10.1182/blood-2019-126354 - DOI - PubMed
  29.  
    1. Jajosky R, Floyd M, Thompson T, Shikle J. Validation of the PLASMIC score at a University Medical Center. Transfus Apher Sci 2017. Aug;56(4):591-594. 10.1016/j.transci.2017.06.006 - DOI - PubMed
  30.  
    1. Hubbard AR, Heath AB, Kremer Hovinga JA, Subcommittee on von Willebrand Factor . Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost 2015. Jun;13(6):1151-1153. 10.1111/jth.12881 - DOI - PubMed
  31.  
    1. Sarig G. ADAMTS-13 in the Diagnosis and management of thrombotic microangiopathies. Rambam Maimonides Med J 2014. Oct;5(4):e0026. 10.5041/RMMJ.10160 - DOI - PMC - PubMed
  32.  
    1. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998. Nov;339(22):1585-1594. 10.1056/NEJM199811263392203 - DOI - PMC - PubMed
  33.  
    1. Thouzeau S, Capdenat S, Stépanian A, Coppo P, Veyradier A. Evaluation of a commercial assay for ADAMTS13 activity measurement. Thromb Haemost 2013. Oct;110(4):852-853. 10.1160/TH13-05-0393 - DOI - PubMed
  34.  
    1. Joly B, Stepanian A, Hajage D, Thouzeau S, Capdenat S, Coppo P, et al. . Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement. Thromb Res 2014. Nov;134(5):1074-1080. 10.1016/j.thromres.2014.09.006 - DOI - PubMed
  35.  
    1. Mansouri Taleghani M, von Krogh AS, Fujimura Y, George JN, Hrachovinová I, Knöbl PN, et al. . Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie 2013. May;33(2):138-143. 10.5482/HAMO-13-04-0026 - DOI - PubMed
  36.  
    1. Lotta LA, Wu HM, Mackie IJ, Noris M, Veyradier A, Scully MA, et al. . Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012. Jul;120(2):440-448. 10.1182/blood-2012-01-403113 - DOI - PMC - PubMed
  37.  
    1. Bukowski RM, Hewlett JS, Harris JW, Hoffman GC, Battle JD, Jr, Silverblatt E, et al. . Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. Semin Hematol 1976. Jul;13(3):219-232. - PubMed
  38.  
    1. Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977. Sep;50(3):413-417. 10.1182/blood.V50.3.413.413 - DOI - PubMed
  39.  
    1. Ito K, Hattori A, Hirosawa S, Takamatsu J, Kakishita E, Fujimura K. [Changes and progress in the treatment of TTP–protocols of therapeutic plasma infusion and plasma exchange–therapeutic results by the Japanese and Canadian Study Groups]. Nihon Rinsho 1993. Jan;51(1):184-186. - PubMed
  40.  
    1. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Canadian Apheresis Study Group . Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991. Aug;325(6):393-397. 10.1056/NEJM199108083250604 - DOI - PubMed
  41.  
    1. Ito K. [Thrombotic thrombocytopenic purpura–recent development of TTP study]. Nihon Rinsho 1993. Jan;51(1):114-116. - PubMed
  42.  
    1. Toussaint-Hacquard M, Coppo P, Soudant M, Chevreux L, Mathieu-Nafissi S, Lecompte T, et al. . Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study. Transfusion 2015. Oct;55(10):2445-2451. 10.1111/trf.13229 - DOI - PubMed
  43.  
    1. Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC, Adams G, et al. Members of the Canadian Apheresis Group . Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Br J Haematol 1996. Aug;94(2):383-386. 10.1046/j.1365-2141.1996.d01-1800.x - DOI - PubMed
  44.  
    1. Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Besa EC, et al. North American TTP Group . Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001;16(1):19-22. 10.1002/jca.1003 - DOI - PubMed
  45.  
    1. Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C, et al. Italian TTP Study Group . High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 2010. Jun;89(6):591-596. 10.1007/s00277-009-0877-5 - DOI - PubMed
  46.  
    1. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, et al. . ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020. Oct;18(10):2496-2502. 10.1111/jth.15010 - DOI - PMC - PubMed
  47.  
    1. Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008;23(5):151-156. 10.1002/jca.20172 - DOI - PubMed
  48.  
    1. Rubia J, Moscardó F, Gómez MJ, Guardia R, Rodríguez P, Sebrango A, et al. Grupo Español de Aféresis (GEA) . Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci 2010. Dec;43(3):299-303. 10.1016/j.transci.2010.09.018 - DOI - PubMed
  49.  
    1. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, et al. French Thrombotic Microangiopathies Reference Center. Experience of the French Thrombotic Microangiopathies Reference Center . Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Crit Care Med 2012. Jan;40(1):104-111. 10.1097/CCM.0b013e31822e9d66 - DOI - PubMed
  50.  
    1. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. . Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007. Feb;136(3):451-461. 10.1111/j.1365-2141.2006.06448.x - DOI - PubMed
  51.  
    1. Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution’s experience and review of the literature. Transfusion 2005. Jan;45(1):41-49. 10.1111/j.1537-2995.2005.03146.x - DOI - PubMed
  52.  
    1. Cataland SR, Jin M, Lin S, Kennedy MS, Kraut EH, George JN, et al. . Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 2007. Nov;139(3):486-493. 10.1111/j.1365-2141.2007.06819.x - DOI - PubMed
  53.  
    1. Thejeel B, Garg AX, Clark WF, Liu AR, Iansavichus AV, Hildebrand AM. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review. Am J Hematol 2016. Jun;91(6):623-630. 10.1002/ajh.24339 - DOI - PubMed
  54.  
    1. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, et al. . N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011. Feb;121(2):593-603. 10.1172/JCI41062 - DOI - PMC - PubMed
  55.  
    1. Plaimauer B, Kremer Hovinga JA, Juno C, Wolfsegger MJ, Skalicky S, Schmidt M, et al. . Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011. May;9(5):936-944. 10.1111/j.1538-7836.2011.04224.x - DOI - PubMed
  56.  
    1. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013. Jan;368(1):90-92. 10.1056/NEJMc1213206 - DOI - PubMed
  57.  
    1. Callewaert F, Roodt J, Ulrichts H, Stohr T, van Rensburg WJ, Lamprecht S, et al. . Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012. Oct;120(17):3603-3610. 10.1182/blood-2012-04-420943 - DOI - PubMed
  58.  
    1. Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. HERCULES Investigators . HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019. Jan;380(4):335-346. 10.1056/NEJMoa1806311 - DOI - PubMed
  59.  
    1. Meo SA, Mahesar AL, Sheikh SA, Sattar K, Bukhari IA. Research productivity of Gulf Cooperation Council (GCC) countries in science and social sciences. J Pak Med Assoc 2016. Oct;66(10):1307-1313. - PubMed

Page Navigation